Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia-Reference-Cited by-同舟云学术

Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia

Published:2019-05-23 Issue:11 Volume:22 Page:1105-1112
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Song Xue¹,El Khoury Antoine C.²,Brouillette Matthew¹,Smith David¹,Joshi Kruti²

Affiliation:

1. Oncology and Life Sciences, IBM Watson Health, Cambridge, MA, USA;

2. US Real World Value & Evidence, Janssen Pharmaceuticals, Inc, Titusville, NJ, USA

Funder

Janssen Scientific Affairs, LLC

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://tandfonline.com/doi/pdf/10.1080/13696998.2019.1615927

Reference41 articles.

1. Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective

2. National Institutes of Mental Health. Schizophrenia overview. 2016. [cited 2018, September 19]. Available from: https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml

3. National Institutes of Mental Health. Schizophrenia statistics. 2018. [cited 2018, September 19]. Available from: https://www.nimh.nih.gov/health/statistics/schizophrenia.shtml

4. An evaluation of variation in published estimates of schizophrenia prevalence from 1990─2013: a systematic literature review

5. Health Insurance Coverage Among Persons With Schizophrenia in the United States

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-Hospital Use of Long-Acting Injectable Antipsychotics and Readmission Risk in Patients With First-Admission Schizophrenia in Taiwan;JAMA Network Open;2024-06-17

2. Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia;Journal of Managed Care & Specialty Pharmacy;2024-06

3. A systematic review of the real-world effectiveness and economic and humanistic outcomes of selected oral antipsychotics among patients with schizophrenia in the United States: Updating the evidence and gaps;Journal of Managed Care & Specialty Pharmacy;2024-02-03

4. Persistence and adherence to second-generation antipsychotic long-acting injectable medications for schizophrenia: A comparative study in the Australian context;Australasian Psychiatry;2022-12-07

5. Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting;Psychiatry Research;2022-11